Kala Pharmaceuticals Inc (KALA) Receives $36.00 Average Target Price from Analysts

Share on StockTwits

Kala Pharmaceuticals Inc (NASDAQ:KALA) has been given a consensus recommendation of “Buy” by the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $36.00.

KALA has been the topic of several analyst reports. BidaskClub raised shares of Kala Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, April 4th. ValuEngine raised shares of Kala Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Zacks Investment Research raised shares of Kala Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, April 4th. Finally, Wedbush reissued an “outperform” rating and issued a $47.00 price target on shares of Kala Pharmaceuticals in a report on Wednesday, June 20th.

Kala Pharmaceuticals traded down $0.19, reaching $13.62, on Friday, MarketBeat Ratings reports. 2,401 shares of the company were exchanged, compared to its average volume of 174,068. Kala Pharmaceuticals has a 12 month low of $11.81 and a 12 month high of $26.75. The firm has a market capitalization of $335.28 million and a P/E ratio of -2.33. The company has a current ratio of 20.40, a quick ratio of 20.40 and a debt-to-equity ratio of 0.25.

Kala Pharmaceuticals (NASDAQ:KALA) last announced its earnings results on Thursday, May 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.46). equities research analysts anticipate that Kala Pharmaceuticals will post -1.97 EPS for the current fiscal year.

A number of institutional investors have recently made changes to their positions in KALA. Millennium Management LLC increased its holdings in Kala Pharmaceuticals by 865.5% in the 1st quarter. Millennium Management LLC now owns 998,319 shares of the company’s stock valued at $15,803,000 after buying an additional 894,919 shares during the period. BlackRock Inc. increased its holdings in Kala Pharmaceuticals by 76.1% in the 4th quarter. BlackRock Inc. now owns 738,050 shares of the company’s stock valued at $13,646,000 after buying an additional 319,043 shares during the period. Wells Fargo & Company MN increased its holdings in Kala Pharmaceuticals by 74.5% in the 4th quarter. Wells Fargo & Company MN now owns 286,694 shares of the company’s stock valued at $5,301,000 after buying an additional 122,425 shares during the period. Asymmetry Capital Management L.P. increased its holdings in Kala Pharmaceuticals by 894.1% in the 1st quarter. Asymmetry Capital Management L.P. now owns 134,250 shares of the company’s stock valued at $2,125,000 after buying an additional 120,746 shares during the period. Finally, Emory University bought a new stake in Kala Pharmaceuticals in the 4th quarter valued at $1,827,000. 76.84% of the stock is currently owned by hedge funds and other institutional investors.

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Its product candidates include KPI-121 1.0%, which has completed Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; INVELTYS that has completed Phase III clinical trials for the temporary relief of the signs and symptoms of dry eye disease; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

Analyst Recommendations for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.